Regencell Bioscience (RGC) Stock Analysis

What Regencell Bioscience does

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Key metrics

ETFs linked to RGC

Broad-market and Healthcare sector ETFs an investor holding Regencell Bioscience is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RGC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Regencell Bioscience?

Regencell Bioscience trades under the ticker RGC on NASDAQ.

Which exchange is RGC listed on?

RGC is listed on NASDAQ.

What sector does Regencell Bioscience operate in?

Regencell Bioscience is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze RGC in a portfolio?

PortView shows RGC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.